{"id":21,"date":"2016-06-23T16:10:42","date_gmt":"2016-06-23T14:10:42","guid":{"rendered":"http:\/\/henkjanout.nl\/?page_id=21"},"modified":"2021-11-05T06:15:37","modified_gmt":"2021-11-05T05:15:37","slug":"publicaties","status":"publish","type":"page","link":"https:\/\/henkjanout.nl\/en\/publicaties\/","title":{"rendered":"Scientific publications"},"content":{"rendered":"

More details on citations on\u00a0Google Scholar Public Profile<\/a><\/em><\/h4>\n
\n
    \n
  1. Out HJ, Derksen RHWM, Christiaens GCML. Systemische lupus erythematosus en zwangerschap. Amstelveen: Nationale Vereniging LE-patienten, 1988. ISBN: 90-71141-33-0.<\/li>\n
  2. Derksen RHWM, Out HJ, Christiaens GCML. Lupus erythematosus disseminatus en zwangerschap.\u00a0Ned Tijdschr Geneeskd<\/em>\u00a01989; 133: 1025-1029.<\/li>\n
  3. Out HJ, Derksen RHWM, Christiaens GCML. Systemic lupus erythematosus and pregnancy.\u00a0Obstet Gynecol Surv<\/em>\u00a01989; 44: 585-591.<\/li>\n
  4. Out HJ, De Groot PhG, Hasselaar P, Van Vliet M, Derksen RHWM. Fluctuations of anti-cardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study.\u00a0Ann Rheum Dis<\/em>\u00a01989; 48: 1023-1028.<\/li>\n
  5. Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RHWM, Machin SJ, Barquinero LJ, Out HJ, Harris EN, Vilardell-Torres M, Hughes GRV. The “primary” antiphospholipid syndrome: Major clinical and serological features.\u00a0Medicine (Baltimore)<\/em>\u00a01989; 68: 366-374.<\/li>\n
  6. Out HJ, Kater L, Derksen RHWM. Antiphospholipid antibodies: risk factors or only markers for thrombosis, fetal loss and thrombocytopenia? (editorial)\u00a0Neth J Med\u00a0<\/em>1990; 36: 177-181.<\/li>\n
  7. Out HJ, De Groot PhG, Van Vliet M, Nieuwenhuis HK, De Gast GC, Derksen RHWM. Antibodies to platelets in patients with anti-phospholipid antibodies.\u00a0Blood\u00a0<\/em>1991; 77: 2655-2659.<\/li>\n
  8. Out HJ, Bruinse HW, Christiaens GCML, Van Vliet M, Meilof JT, De Groot PhG, Smeenk RJT, Derksen RHWM. The prevalence of anti-phospholipid antibodies in patients with fetal loss.\u00a0Ann Rheum Dis<\/em>\u00a01991; 50: 553-557.<\/li>\n
  9. Out HJ, Kooijman CD, Bruinse HW, Derksen RHWM. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies.\u00a0Eur J Obstet Gynaecol Reprod Biol<\/em>\u00a01991; 41: 179-186.<\/li>\n
  10. Out HJ, Bruinse HW, Derksen RHWM. Antiphospholipid antibodies and pregnancy loss.\u00a0Hum Reprod<\/em>\u00a01991; 6: 889-897.<\/li>\n
  11. Out HJ, Van Vliet M, De Groot PhG, Derksen RHWM. A prospective study on fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus.\u00a0Ann Rheum Dis<\/em>\u00a01992; 51: 353-357.<\/li>\n
  12. Out HJ, Bruinse HW, Christiaens GCML, Van Vliet M, De Groot PhG, Nieuwenhuis HK, Derksen RHWM. A prospective, controlled multicenter study on the obstetric risks of pregnant women with anti-phospholipid antibodies.\u00a0Am J Obstet Gynecol<\/em>\u00a01992; 167: 26-32.<\/li>\n
  13. Derksen RHWM, Out HJ, Blokzijl L, De Groot PhG. Lupus anticoagulant in pregnancy (letter).\u00a0Clin Exp Rheumatol<\/em>\u00a01992; 10: 323-324.<\/li>\n
  14. Out HJ, Derksen RHWM, De Groot PhG. Lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus.\u00a0Ann Rheum Dis<\/em>\u00a01992; 51: 1021-1022 (reply to letter).<\/li>\n
  15. Out HJ. Antifosfolipiden antistoffen: Diagnostiek en klinische betekenis.\u00a0Analyse\u00a0<\/em>1992; 47: 246-248.<\/li>\n
  16. Out HJ, Mannaerts BMJL, Driessen SGAJ, Coelingh Bennink HJT. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle-stimulating hormone (Puregon\u00a0vs<\/em>\u00a0Metrodin) in in-vitro fertilization.\u00a0Hum Reprod<\/em>\u00a01995; 10: 2534-2540.<\/li>\n
  17. Hedon B, Out HJ, Hugues JN, Camier B, Cohen J, Lopes P, Zorn JR, Van der Heijden B, Coelingh Bennink HJT. Efficacy and safety of recombinant FSH (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilisation: A prospective, randomised, assessor-blind, multicentre trial.\u00a0Hum Reprod<\/em>\u00a01995; 10; 3102-3106.<\/li>\n
  18. Hedon B, Out HJ, Hugues JN, Camier B, Cohen J, Lopes P, Zorn JR, Van der Heijden B, Coelingh Bennink HJT. Effacit\u00e9 et s\u00e9curit\u00e9 d\u2019emploi d\u2019une FSH recombin\u00e9e (Puregon) apr\u00e8s blocage hypophysaire par la tritoreline chez des femmes infertiles soumises \u00e0 une FIV – etude clinique multicentrique, prospective, randomis\u00e9e, lue en aveugle.\u00a0Jobgyn<\/em>\u00a01996; 4: 35-42<\/li>\n
  19. Out HJ, Schnabel PG, Rombout F, Geurts TBP, Bosschaert MAR, Coelingh Bennink HJT. A bioequivalence study of two urinary follicle stimulating hormone preparations: Follegon and Metrodin.\u00a0Hum Reprod<\/em>\u00a01996; 11: 61-63.<\/li>\n
  20. Mannaerts BMJL, Rombout F, Out HJ, Coelingh Bennink HJT. Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy.\u00a0Hum Reprod Update<\/em>\u00a01996: 2: 153-161.<\/li>\n
  21. Out HJ, Mannaerts BMJL, Driessen SGAJ, Coelingh Bennink HJT. Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: More oocytes, more pregnancies. Results from five comparative studies.\u00a0Hum Reprod Update<\/em>\u00a01996: 2: 162-171.<\/li>\n
  22. Geurts TBP, Peters MJH, van Bruggen JGC, de Boer WHJ, Out HJ. Puregon – (Org 32489) – recombinant human follicle-stimulating hormone. Drugs of Today\u00a0<\/em>1996; 32: 239-258.<\/li>\n
  23. Out HJ. Future preparations. From 75 IU freeze-dried cakes of HMG to 50 IU lyospheres of recombinant follicle-stimulating hormone.\u00a0Orgyn\u00a0<\/em>1996; 3: 29-31.<\/li>\n
  24. Out HJ, Coelingh Bennink HJT. Puregon in assisted reproduction. More oocytes, more pregnancies.\u00a0Puregon Orgyn special issue<\/em>\u00a01996; 7-13<\/li>\n
  25. Out HJ, Olijve W, Coelingh Bennink HJT. The coming of wonders [Letter].\u00a0Fertil Steril\u00a0<\/em>1997;\u00a0<\/em>67: 411-413.<\/li>\n
  26. Out HJ, Reimitz PE, Coelingh Bennink HJT. A prospective, randomized, study to assess the tolerance and efficacy of intramuscular and subcutaneous administration of recombinant follicle-stimulating hormone (Puregon).\u00a0Fertil Steril\u00a0<\/em>1997; 67: 278-283.<\/li>\n
  27. Out HJ, Driessen SGAJ, Mannaerts BMJL, Coelingh Bennink HJT. Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins.\u00a0Fertil Steril<\/em>\u00a01997; 68: 138-142<\/li>\n
  28. Jones HW Jr, Out HJ, Hoomans EHM, Driessen SGAJ, Coelingh Bennink HJT. Cryopreservation: The practicalities of evaluation.\u00a0Hum Reprod<\/em>\u00a01997; 12: 1522-1524.<\/li>\n
  29. Out HJ, Donderwinkel PFJ, Fauser BCJM, Coelingh Bennink HJT. The use of a high-dose combined oral contraceptive preparation for suppression of endogenous gonadotrophins in a bioequivalence study of two urinary gonadotrophin preparations.\u00a0Middle East Fertility Society Journal<\/em>\u00a01997; 2: 120-127.<\/li>\n
  30. Duijkers IJM, Klipping C, Mulders TMT, Out HJ, Coelingh Bennink HJT, Vemer HM. Pharmacodynamics and pharmacokinetics after repeated subcutaneous administration of three gonadotropin preparations.\u00a0Hum Reprod<\/em>\u00a01997; 12: 2379-2384.<\/li>\n
  31. Coelingh Bennink HJT, Fauser BCJM, Out HJ, for the European Puregon Collaborative Anovulation Study Group. Recombinant FSH (Puregon) is more efficient than urinary FSH (Metrodin) in clomiphene-resistant normogonadotropic chronic anovulatory women: A prospective, multicenter, assessor-blind, randomised, clinical trial.\u00a0Fertil Steril<\/em>\u00a01998; 69: 19-25.<\/li>\n
  32. Devroey P, Tournaye H, Van Steirteghem A, Hendrix P, Out HJ. The use of a 100 IU starting dose of recombinant FSH (Puregon) in in-vitro fertilization.\u00a0Hum Reprod<\/em>\u00a01998; 13: 565-566.<\/li>\n
  33. Out HJ, Coelingh Bennink HJT. Clomiphene citrate in the twenty-first century: An anachronism?\u00a0Assisted Reproduction Reviews<\/em>\u00a01998; 8: 94-101.<\/li>\n
  34. Out HJ, Coelingh Bennink HJT. Drawing conclusions from imperfect data – Isn\u2019t that what science does all the time? [Reply-to-letter]\u00a0Fertil Steril<\/em>\u00a01998; 70: 385.<\/li>\n
  35. Out HJ, Coelingh Bennink HJT. Clomiphene citrate or gonadotrophins for induction of ovulation?\u00a0Hum Reprod<\/em>\u00a01998; 13: 2358-2361.<\/li>\n
  36. Jansen CAM, Van Os HC, Out HJ, Coelingh Bennink HJT. A prospective randomised clinical trial comparing recombinant follicle-stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-downregulated in-vitro fertilization patients.\u00a0Hum Reprod<\/em>\u00a01998; 13: 2995-2999.<\/li>\n
  37. Out HJ, Olijve W, Coelingh Bennink HJT. Recombinant FSH (Puregon): biotechnology and clinical results.\u00a0Cell\u00a0<\/em>1998; 30: 150-155,<\/li>\n
  38. Out HJ. New stimulation regimens with recombinant FSH (Puregon) in in-vitro fertilization.\u00a0Eur J Obstet Gynecol Reprod Biol<\/em>\u00a01999; 85: 21-22.<\/li>\n
  39. Devroey P, Tournaye H, Van Steirteghem A, Hendrix P, Out HJ. Ovarian stimulation [Reply-to-letter].\u00a0Hum Reprod<\/em>\u00a01999; 14: 865.<\/li>\n
  40. Out HJ, Mannaerts BMJL, Driessen SGAJ, Coelingh Bennink HJT. A pregnancy and children follow-up study of three randomised clinical trials with recombinant follicle stimulating hormone (Puregon) in in-vitro fertilization.\u00a0Middle East Fertility Society Journal<\/em>\u00a01999; 4: 28-34.<\/li>\n
  41. Out HJ, Lindenberg S, Mikkelsen AL, Eldar-Geva T, Healy DL, Leader A, Rodriguez-Escudero FJ, Garcia-Velasco JA, Pellicer A. A prospective, randomised, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon\u00ae) in women undergoing controlled ovarian hyperstimulation.\u00a0Hum Reprod<\/em>\u00a01999; 14: 622-627.<\/li>\n
  42. Out HJ. Anovulatory infertility and the role of recombinant follicle-stimulating hormone (Recagon).\u00a0J Indian Med Assoc<\/em>\u00a01999; 97: 37-40.<\/li>\n
  43. Kahn JA, Sunde A, von During V, Out HJ. A prospective randomized comparative cohort study of either recombinant FSH (Puregon) or urinary FSH (Metrodin) in in vitro fertilization treatment. Middle East Fertility Society Journal<\/em>\u00a01999; 4: 206-214.<\/li>\n
  44. Out HJ, Coelingh Bennink HJT, De Laat WNGM. What are the clinical benefits of recombinant gonadotrophins? The development of recombinant follicle stimulating hormone (Puregon\u00ae): A scientific business.\u00a0Hum Reprod<\/em>\u00a01999; 14: 2189-2190.<\/li>\n
  45. Out HJ, Braat DDM, Lintsen BME, Gurgan T, Bukulmez O, Gokmen O, Keles G, Caballero P, Gonzalez JM, Fabregues F, Balasch J, Roulier, R. Increasing the daily dose of recombinant follicle-stimulating hormone (Puregon\u00ae) does not compensate for the age-related decline in retrievable oocytes after controlled ovarian hyperstimulation.\u00a0Hum Reprod<\/em>\u00a02000; 15: 29-35.<\/li>\n
  46. Out HJ, Hoomans E, de Laat WNGM. Meta-analysis on rFSH versus uFSH. [Letter-to-the-editor].\u00a0Hum Reprod<\/em>\u00a02001; 16: 593-595.<\/li>\n
  47. Out HJ, David I, Ron-El R, Friedler S, Shalev E, Geslevich J, Dor J, Shulman A, Ben-Rafael Z, Fisch B, Dirnfeld M. A randomised double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles.\u00a0Hum Reprod<\/em>\u00a02001; 16: 1104-1109<\/li>\n
  48. The Latin-American Puregon IVF study group. A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle stimulating hormone in women undergoing in vitro fertilisation.\u00a0Fertil Steril<\/em>\u00a02001; 76: 950-956 (writer of the protocol and initial co-ordinator of the trial; writer of the manuscript, corresponding author).<\/li>\n
  49. Sykes D, Out HJ, Palmer SJ, van Loon J. The cost-effectiveness of in vitro fertilisation in the United Kingdom: A comparison of three gonadotrophin treatments.\u00a0Hum Reprod<\/em>\u00a02001; 16: 2557-2562.<\/li>\n
  50. Out HJ, Mannaerts BMJL. The gonadotrophin releasing hormone antagonist ganirelix: History and introductory data. Human Fertility<\/em>\u00a02002; 5: G5-G12.<\/li>\n
  51. The oral contraceptive and hemostasis study group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: Conclusions from a large randomised multicenter study.\u00a0Contraception<\/em>\u00a02003; 67: 173-185 (corresponding author only).<\/li>\n
  52. Out HJ, Rutherford A, Fleming R, Tay CCK, Trew G, Ledger W, Cahill D. A randomised double-blind multi-centre clinical trial comparing a starting dose of 150 and 200 IU of recombinant FSH in women treated with the GnRH-antagonist ganirelix for assisted reproduction.\u00a0Hum Reprod<\/em>\u00a02004; 19: 90-95.<\/li>\n
  53. Out HJ. Recombinant follicle-stimulating hormone: Gold standard or not?\u00a0Reproductive Biomedicine Online<\/em>\u00a02005; 11: 536-539.<\/li>\n
  54. Out HJ. Ten years of Puregon. Fertility Matters Special 2006<\/li>\n
  55. Out HJ, Thomas LE. Optimizing the gonadotrophin dose regimen.\u00a0Int Surg<\/em>\u00a02006; 91: S15-S24.<\/li>\n
  56. Out HJ, Broekmans AW. Wetenschappelijke business. Kritiek op geneesmiddelenonderzoek is ongegrond.\u00a0Medisch Contact<\/em>\u00a02007; 62: 1024-7.<\/li>\n
  57. Out HJ, Broekmans AW. Letter-to-the -editor on editorial Vandenbroucke and Van der Meer: \u201cOnafhankelijkheid van medici en van medisch onderzoek\u201d.\u00a0Ned Tijdschr Geneeskd<\/em>\u00a02009; 153: A749.<\/li>\n
  58. Out HJ. Gastredactioneel: \u201cSlecht voor Uw gezondheid?\u201d\u00a0C2W Medicines<\/em>\u00a02009; 3: 6.<\/li>\n
  59. Out HJ. The Randomized Controlled Clinical Trial. EJHP Practice<\/em>\u00a02010; 16 (5): 52-53.<\/li>\n
  60. Van Lent M, Out HJ. Industry tie may be benchmark of quality [Letter-to-the-editor].\u00a0Br Med J<\/em>\u00a02011; 343: 493.<\/li>\n
  61. Out HJ, Lisman J. “Kwaliteit van geneesmiddeladvertenties in NTvG en PW” [Letter-to-the-editor]\u00a0Ned Tijdsch Geneeskd<\/em>\u00a02012; 156: A3999<\/li>\n
  62. Van Lent, Out HJ. Effect of funding source on publication bias is not so clear cut [Letter-to-the-editor].\u00a0Br Med J<\/em>\u00a02013; 347: f7582.<\/li>\n
  63. Van Lent M, Overbeke J, Out HJ. Recommendations for a uniform assessment of publication bias related to funding source.\u00a0BMC Medical Research Methodology\u00a0<\/em>2013; 13: 120<\/a><\/li>\n
  64. Out HJ. Data from industry funded trials are reliable enough to be published [Letter-to-the-editor].\u00a0Br Med J<\/em>\u00a02014; 348: g1298.<\/li>\n
  65. van Lent M, Overbeke J, Out HJ. Role of Editorial and Peer Review Processes in Publication Bias: Analysis of Drug Trials Submitted to Eight Medical Journals.\u00a0PLOS ONE\u00a0<\/em>2014; 9(8): e104846<\/a><\/li>\n
  66. Van Lent M, Rongen GA, Out HJ. Shortcomings of protocols of drug trials in relation to sponsorship as identified by Research Ethics Committees: analysis of comments raised during ethical review.\u00a0BMC Medical Ethics 2014,\u00a0<\/em>15:83<\/a><\/li>\n
  67. Van Lent M, IntHout J, Out HJ. Differences between information in registries and articles did not influence publication acceptance\u00a0J Clin Epidemiol\u00a0<\/em>2015; 68: 1059-1067<\/a><\/li>\n
  68. Van Lent M, IntHout J, Out HJ. Peer Review Comments on Drug Trials Submitted to Medical Journals Differ Depending on Sponsorship, Results, and Acceptance: A Retrospective Cohort Study.\u00a0BMJ Open<\/em>\u00a02015;5:e007961<\/a><\/li>\n
  69. Out HJ. Recognize the pivotal role of the private sector. Rapid response to editorial Mazzucato M: High cost of new drugs. BMJ <\/em>2016; 354: i4136<\/a> and https:\/\/www.bmj.com\/content\/354\/bmj.i4136\/rr-4<\/a><\/li>\n
  70. Out HJ. De invloed van de financieringsbron op de kwaliteit en integriteit van klinisch geneesmiddelenonderzoek. Podium voor Bioethiek<\/em> 2016; 23 (3): 7-10<\/a>.<\/li>\n
  71. Devall AJ, Out HJ, Mol BWJ, Duffy JMN, Collura B, Dyer S. Coordination and planning of clinical research on a national and global level. Fertil Steril<\/em> 2020; 113: 1100-6.<\/li>\n
  72. Christin-Maitre S, Zitzmann M, Lambalk C, Pitteloud N, Dubourdieu S, Hildebrandt T, Creutzberg E, Out HJ, de Geyter C. Diagnosis and treatment options for hypogonadotropic hypogonadism in adolescents, men and women \u2013 Review of an expert meeting. European Gynecology and Obstetrics<\/em> 2020; 2: 82-89.<\/li>\n
  73. Bahmanyar ER, Out HJ, van Duin M. [Clinical Opinion] Women and babies are dying from inertia: a collaborative framework for obstetric drug development is urgently needed. Am J Obstet Gynecol<\/em> 2021; 225: 43-50.<\/li>\n<\/ol>\n

    Chapters in books and other<\/h1>\n
      \n
    1. Out HJ. Co-ordinator Excerpts on Human Reproduction, number 1, May 1996. The development of Puregon, a recombinant FSH. Oxford University Press.<\/li>\n
    2. Out HJ. Co-editor: Recombinant FSH (Puregon). Preclinical and clinical experience. Parthenon Publishing Group, 1996, Carnforth, UK. ISBN 1-85070-746-4.<\/li>\n
    3. Geurts TBJ, Peters MJH, van Bruggen JGC, de Boer W, Out HJ. Gonadotrophins into the next century: the research and development of Puregon. In: Practical Guide to Reproductive Medicine. Edited by Rainsbury PA, Viniker DA. Parthenon Publishing Group, 1997, Carnforth, UK. ISBN: 1-85070-727-8.<\/li>\n
    4. Mannaerts BMJL, Rombout F, Out HJ, Coelingh Bennink HJT. Clinical profiling of recombinant follicle-stimulating hormone (rFSH; Puregon): Relationship between serum FSH and efficacy. In: Coutifaris C, Mastroianni L, eds. New Horizons in Reproductive Medicine; the Proceedings of the 9th World Congress in Human Reproduction, Philadelphia, 1996. New York: Parthenon, 1997: 169-79 (The International Congress, Symposium and Seminar Series; Volume 12).<\/li>\n
    5. Out HJ. Co-ordinator Excerpts on Human Reproduction, number 1, October 1997. Further studies on Puregon, a recombinant FSH. Oxford University Press.<\/li>\n
    6. Out HJ. Puregon in patients with chronic anovulation. In: Infertility and Assisted Reproductive Technology. From Research to Therapy. Edited by Ambrosini A, Melis GB, Dalla Pria S, Dessole S.. Monduzzi Editore, Bologna, 1997.<\/li>\n
    7. Out HJ, Olijve W, Mannaerts BMJL, Coelingh Bennink, HJT. FSH recombinante (Puregon) en Reproduccion Asistida. In: Esterilidad, edited by Comparato MR. Segunda edicion, Argentina.<\/li>\n
    8. Out HJ. Follitropin beta (Puregon). In: Biopharmaceuticals, an Industrial Perspective. Edited by Gary Walsh, Brendan Murphy. Kluwer Academic Publishers, Dordrecht, 1999. ISBN 0-7923-5746-9.<\/li>\n
    9. Out HJ. Co-ordinator monograph Surveillance 1998 (Fertility & Sterility 1999, volume 71, supplement 2) 1999), edited by Howard Jones Jr and Jean Cohen.<\/li>\n
    10. Out HJ, Hoomans EHM. New stimulation regimens with recombinant follicle stimulating hormone. Proceedings Third World Congress of Ovulation Induction. Editor: Marco Filicori. CIC Edizioni Internazionali, Rome, 2001.<\/li>\n
    11. Out HJ. Should treatment with clomiphene continue? Proceedings 2nd\u00a0World Congress on Controversies in Obstetrics, Gynecology and Infertility. Monduzzi Editore, Bologna, 2001.<\/li>\n
    12. Out HJ. Side effects of drugs commonly used for induction of ovulation. In: Sathanandan SM and Jacobs HS. Handbook for ovulation induction. Imperial College Press, London, 2002.<\/li>\n
    13. Out HJ. Synthesis and pharmacology of recombinant follicle-stimulating hormone, pp59-67. In: Revelli A, Tur-Kaspa I, Holte JG, Massobrio M, editors: Biotechnology of Human Reproduction. Parthenon, London, 2003.<\/li>\n
    14. Out HJ. Co-ordinator monograph Surveillance 2004 (Fertility & Sterility 2004, volume 81; Supplement 4), edited by Howard Jones Jr and Jean Cohen.<\/li>\n
    15. Out HJ. \u201c\u2026.., diens woord men spreekt? De financieringsbron als kwaliteitskenmerk van klinisch geneesmiddelenonderzoek.\u201d Inaugural oration. Radboudumc, 2011<\/li>\n
    16. Out HJ, Van Meurs P, Van Olden R, 2013, editors, \u201cHandboek Farmaceutische Geneeskunde\u201d, Bohn Stafleu Van Loghem, Houten, The Netherlands<\/li>\n
    17. Van Lent M, Out HJ. Integriteit en kwaliteit van klinisch geneesmiddelenonderzoek, 2013 In: \u2028\u201cHandboek Farmaceutische Geneeskunde\u201d,\u00a0<\/em>Bohn Stafleu van Loghum, Houten, The Netherlands.<\/li>\n
    18. Out HJ. De pil en trombose. In: Waar maken artsen zich druk om? Selectie van blogs op Artsennet 2013, Reed Amsterdam.<\/li>\n
    19. Out HJ. Vage vergoedingsdiscussies vertragen toegang tot nieuwe medicijnen. In: Snelle toelating of bewezen effectief en veilig? Twintig columnisten geven hun visie op het versneld toelaten van nieuwe geneesmiddelen. Jubileumuitgave Instituut voor Verantwoord Medicijngebruik, November 2015.<\/li>\n
    20. Out HJ. \u201cLeve het Geneesmiddel! Over de verdiensten van de farmaceutische industrie.\u201d Prometheus, September 2016<\/li>\n<\/ol>\n

      <\/p>\n","protected":false},"excerpt":{"rendered":"

      More details on citations on\u00a0Google Scholar Public Profile Out HJ, Derksen RHWM, Christiaens GCML. Systemische lupus erythematosus en zwangerschap. Amstelveen: Nationale Vereniging LE-patienten, 1988. ISBN: 90-71141-33-0. Derksen RHWM, Out HJ, Christiaens GCML. Lupus erythematosus disseminatus en zwangerschap.\u00a0Ned Tijdschr Geneeskd\u00a01989; 133: … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"translation":{"provider":"WPGlobus","version":"3.0.2","language":"en","enabled_languages":["nl","en"],"languages":{"nl":{"title":true,"content":true,"excerpt":false},"en":{"title":true,"content":true,"excerpt":false}}},"yoast_head":"\nScientific publications | Henk Jan Out<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/henkjanout.nl\/en\/publicaties\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Scientific publications | Henk Jan Out\" \/>\n<meta property=\"og:url\" content=\"https:\/\/henkjanout.nl\/en\/publicaties\/\" \/>\n<meta property=\"og:site_name\" content=\"Henk Jan Out\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-05T05:15:37+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@Henkjanout\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/henkjanout.nl\/en\/publicaties\/\",\"url\":\"https:\/\/henkjanout.nl\/en\/publicaties\/\",\"name\":\"Scientific publications | Henk Jan Out\",\"isPartOf\":{\"@id\":\"https:\/\/henkjanout.nl\/en\/#website\"},\"datePublished\":\"2016-06-23T14:10:42+00:00\",\"dateModified\":\"2021-11-05T05:15:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/henkjanout.nl\/en\/publicaties\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/henkjanout.nl\/en\/publicaties\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/henkjanout.nl\/en\/publicaties\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/henkjanout.nl\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Scientific publications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/henkjanout.nl\/en\/#website\",\"url\":\"https:\/\/henkjanout.nl\/en\/\",\"name\":\"Henk Jan Out\",\"description\":\"Pharmaceutical physician, writer, consultant\",\"publisher\":{\"@id\":\"https:\/\/henkjanout.nl\/en\/#\/schema\/person\/f6f01033a23ed3e09b979c4bf2503aec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/henkjanout.nl\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\/\/henkjanout.nl\/en\/#\/schema\/person\/f6f01033a23ed3e09b979c4bf2503aec\",\"name\":\"Henk Jan Out\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/henkjanout.nl\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/henkjanout.nl\/wp-content\/uploads\/2016\/06\/image-4.jpeg\",\"contentUrl\":\"https:\/\/henkjanout.nl\/wp-content\/uploads\/2016\/06\/image-4.jpeg\",\"width\":512,\"height\":512,\"caption\":\"Henk Jan Out\"},\"logo\":{\"@id\":\"https:\/\/henkjanout.nl\/en\/#\/schema\/person\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/Henkjanout\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Scientific publications | Henk Jan Out","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/henkjanout.nl\/en\/publicaties\/","og_locale":"en_US","og_type":"article","og_title":"Scientific publications | Henk Jan Out","og_url":"https:\/\/henkjanout.nl\/en\/publicaties\/","og_site_name":"Henk Jan Out","article_modified_time":"2021-11-05T05:15:37+00:00","twitter_card":"summary_large_image","twitter_site":"@Henkjanout","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/henkjanout.nl\/en\/publicaties\/","url":"https:\/\/henkjanout.nl\/en\/publicaties\/","name":"Scientific publications | Henk Jan Out","isPartOf":{"@id":"https:\/\/henkjanout.nl\/en\/#website"},"datePublished":"2016-06-23T14:10:42+00:00","dateModified":"2021-11-05T05:15:37+00:00","breadcrumb":{"@id":"https:\/\/henkjanout.nl\/en\/publicaties\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/henkjanout.nl\/en\/publicaties\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/henkjanout.nl\/en\/publicaties\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/henkjanout.nl\/"},{"@type":"ListItem","position":2,"name":"Scientific publications"}]},{"@type":"WebSite","@id":"https:\/\/henkjanout.nl\/en\/#website","url":"https:\/\/henkjanout.nl\/en\/","name":"Henk Jan Out","description":"Pharmaceutical physician, writer, consultant","publisher":{"@id":"https:\/\/henkjanout.nl\/en\/#\/schema\/person\/f6f01033a23ed3e09b979c4bf2503aec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/henkjanout.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/henkjanout.nl\/en\/#\/schema\/person\/f6f01033a23ed3e09b979c4bf2503aec","name":"Henk Jan Out","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/henkjanout.nl\/en\/#\/schema\/person\/image\/","url":"https:\/\/henkjanout.nl\/wp-content\/uploads\/2016\/06\/image-4.jpeg","contentUrl":"https:\/\/henkjanout.nl\/wp-content\/uploads\/2016\/06\/image-4.jpeg","width":512,"height":512,"caption":"Henk Jan Out"},"logo":{"@id":"https:\/\/henkjanout.nl\/en\/#\/schema\/person\/image\/"},"sameAs":["https:\/\/x.com\/Henkjanout"]}]}},"_links":{"self":[{"href":"https:\/\/henkjanout.nl\/en\/wp-json\/wp\/v2\/pages\/21"}],"collection":[{"href":"https:\/\/henkjanout.nl\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/henkjanout.nl\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/henkjanout.nl\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/henkjanout.nl\/en\/wp-json\/wp\/v2\/comments?post=21"}],"version-history":[{"count":22,"href":"https:\/\/henkjanout.nl\/en\/wp-json\/wp\/v2\/pages\/21\/revisions"}],"predecessor-version":[{"id":551,"href":"https:\/\/henkjanout.nl\/en\/wp-json\/wp\/v2\/pages\/21\/revisions\/551"}],"wp:attachment":[{"href":"https:\/\/henkjanout.nl\/en\/wp-json\/wp\/v2\/media?parent=21"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}